They suggested that an NOD2 antagonist might be a potential agent that could help in treating non-small-cell lung cancer (NSCLC) and synthesized multiple derivatives of MDP, specifically MTC-220. This evidence concerns the gene NOD2 and non-small cell lung carcinoma.